Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Nov;46(5):782–793. doi: 10.1038/bjc.1982.271

Effects of structural variations in synthetic glycolipids upon mitogenicity for spleen lymphocytes, adjuvancy for humoral immune response and on anti-tumour potential.

V N Nigam, J Bonaventure, C Chopra, C A Brailovsky
PMCID: PMC2011167  PMID: 6756461

Abstract

Synthetic glycolipids prepared by esterification of various sugars and sorbitol, and containing various numbers of saturated or unsaturated fatty acid residues as well as bacterial lipid A and lipopolysaccharide, were tested for mitogenicity of splenic cells of Fischer rats and Swiss mice and for the augmentation of humoral immune response against sheep red blood cells in these species. Subsequently a few of the humoral immune-response-enhancing glycolipids were compared with non-enhancers in their anti-tumour activity against 13762 rat mammary carcinoma in inbred Fischer 344 rats and Ehrlich tumour in Swiss mice. They were given systemically after tumour inoculation and intratumourally in squalene and Tween emulsion after intradermal MAC tumour development. It was observed that certain structural characteristics in glycolipids with respect to the type of sugar, the type and number of fatty-acid residues were needed for their adjuvant action of the humoral arm of the immune response. Although humoral immune-response enhancers were somewhat superior to non-enhancers in their anti-tumour activity, the correlation coefficient demonstrated a lack of significant concordance. It is concluded that glycolipids selected for their ability to augment humoral immune responses against standard antigens need not be suspect as tumour-enhancers on the grounds that they would elicit blocking antibodies in vivo against tumour-associated antigens.

Full text

PDF
782

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Behling U. H., Campbell B., Chang C. M., Rumpf C., Nowotny A. Synthetic glycolipid adjuvants. J Immunol. 1976 Sep;117(3):847–851. [PubMed] [Google Scholar]
  2. Bollenback G. N., Parrish F. W. Selective esterification of methyl alpha-D-glucopyranodise. Carbohydr Res. 1971 Apr;17(2):431–438. doi: 10.1016/s0008-6215(00)82551-3. [DOI] [PubMed] [Google Scholar]
  3. Cunningham A. J., Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology. 1968 Apr;14(4):599–600. [PMC free article] [PubMed] [Google Scholar]
  4. El Kappany H., Chopra C., Nigam V. N., Brailovsky C. A., Elhilali M. The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery. Br J Cancer. 1980 Nov;42(5):703–711. doi: 10.1038/bjc.1980.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galanos C., Lüderitz O., Westphal O. Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem. 1971 Dec 22;24(1):116–122. doi: 10.1111/j.1432-1033.1971.tb19661.x. [DOI] [PubMed] [Google Scholar]
  6. Hilleman M. R., Woodhour A. F., Friedman A., Phelps A. H. Studies for safety of adjuvant 65. Ann Allergy. 1972 Aug;30(8):477–483. [PubMed] [Google Scholar]
  7. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  8. Kato A., Ando K., Tamura G., Arima K. Effects of some fatty acid esters on the viability and transplantability of Ehrlich ascites tumor cells. Cancer Res. 1971 May;31(5):501–504. [PubMed] [Google Scholar]
  9. Kinsky S. C. Immunogenicity of liposomal model membranes. Ann N Y Acad Sci. 1978;308:111–123. doi: 10.1111/j.1749-6632.1978.tb22017.x. [DOI] [PubMed] [Google Scholar]
  10. Kreider J. W., Bartlett G. L., Boyer C. M., Purnell D. M. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma. Cancer Res. 1979 Mar;39(3):987–992. [PubMed] [Google Scholar]
  11. Kreider J. W., Bartlett G. L., Purnell D. M. Suitability of rat mammary adenocarcinoma 13762 as a model for BCG immunotherapy. J Natl Cancer Inst. 1976 Apr;56(4):797–802. doi: 10.1093/jnci/56.4.797. [DOI] [PubMed] [Google Scholar]
  12. Lüderitz O., Galanos C., Lehmann V., Mayer H., Rietschel E. T., Weckesser J. Chemical structure and biological activities of lipid A's from various bacterial families. Naturwissenschaften. 1978 Nov;65(11):578–585. doi: 10.1007/BF00364907. [DOI] [PubMed] [Google Scholar]
  13. Nigam V. N., Brailovsky C. A., Chopra C. Maltose tetrapalmitate, a nontoxic immunopotentiator with antitumor activity. Cancer Res. 1978 Oct;38(10):3315–3321. [PubMed] [Google Scholar]
  14. Parr I., Wheeler E., Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer. 1973 May;27(5):370–389. doi: 10.1038/bjc.1973.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rando R. R., Slama J., Bangerter F. W. Functional incorporation of synthetic glycolipids into cells. Proc Natl Acad Sci U S A. 1980 May;77(5):2510–2513. doi: 10.1073/pnas.77.5.2510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ribi E., Milner K. C., Granger D. L., Kelly M. T., Yamamoto K., Brehmer W., Parker R., Smith R. F., Strain S. M. Immunotherapy with nonviable microbial components. Ann N Y Acad Sci. 1976;277(00):228–238. doi: 10.1111/j.1749-6632.1976.tb41700.x. [DOI] [PubMed] [Google Scholar]
  17. Rosenstreich D. L., Asselineau J., Mergenhagen S. E., Nowotny A. A synthetic glycolipid with B-cell mitogenic activity. J Exp Med. 1974 Nov 1;140(5):1404–1409. doi: 10.1084/jem.140.5.1404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. SVENNERHOLM L. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 1957 Jun;24(3):604–611. doi: 10.1016/0006-3002(57)90254-8. [DOI] [PubMed] [Google Scholar]
  19. Seligman S. J. In vitro susceptibility of methicillin-resistant Staphylococcus aureus to sulfamethoxazole and trimethoprim. J Infect Dis. 1973 Nov;128(Suppl):543–p. doi: 10.1093/infdis/128.supplement_3.s543. [DOI] [PubMed] [Google Scholar]
  20. Skidmore B. J., Chiller J. M., Morrison D. C., Weigle W. O. Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitogenic, adjuvant, and immunogenic activities. J Immunol. 1975 Feb;114(2 Pt 2):770–775. [PubMed] [Google Scholar]
  21. Williams T. J., Plessas N. R., Goldstein I. J., Lönngren J. A new class of model glycolipids: synthesis, characterization, and interaction with lectins. Arch Biochem Biophys. 1979 Jun;195(1):145–151. doi: 10.1016/0003-9861(79)90336-9. [DOI] [PubMed] [Google Scholar]
  22. Yarkoni E., Rapp H. J. Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria. Cancer Res. 1979 Feb;39(2 Pt 1):535–537. [PubMed] [Google Scholar]
  23. Yarkoni E., Rapp H. J. Tumor regression after intralesional injection of mycobacterial components emulsified in 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene (squalene), 2,6,10,15,19,23-hexamethyltetracosane (squalane), peanut oil, or mineral oil. Cancer Res. 1979 May;39(5):1518–1520. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES